Free Trial

Acurx Pharmaceuticals (ACXP) Earnings Date, Estimates & Call Transcripts

Acurx Pharmaceuticals logo
$4.48 -0.29 (-6.06%)
As of 01:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Acurx Pharmaceuticals Earnings Summary

Acurx Pharmaceuticals posted Q2 2025 earnings on August 11, 2025, reporting an EPS of -$1.89, which beat analysts' consensus estimates of -$2.00 by $0.11. With a trailing EPS of -$10.69, Acurx Pharmaceuticals' earnings are expected to decrease next year, from ($0.89) to ($2.06) per share.

Upcoming Q3
Earnings Date
Nov. 11Before Market OpensEstimated
Consensus EPS
(Aug. 11)
-$2.00
Actual EPS
(Aug. 11)
-$1.89 Beat By $0.11

Q2 2025 Earnings Resources

ACXP Upcoming Earnings

Acurx Pharmaceuticals' next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Get Acurx Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acurx Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

ACXP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Acurx Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$2.80-$2.80-$2.80
Q2 20251-$2.00-$2.00-$2.00
Q3 20251-$1.61-$1.61-$1.61
Q4 20251-$1.69-$1.69-$1.69

Acurx Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
11/11/2025
(Estimated)
--------
8/11/2025Q2 2025-$2.00-$1.89+$0.11-$1.89--
5/12/2025Q1 2025-$2.80-$2.20+$0.60-$0.11--
3/17/2025Q4 2024-$3.60-$3.20+$0.40-$0.16--
11/12/2024Q3 2024-$4.60-$3.40+$1.20-$0.17--
8/9/2024Q2 2024-$5.60-$5.20+$0.40-$0.26--
5/14/2024Q1 2024-$4.80-$5.60 -$0.80-$0.28--
3/15/2024Q4 2023-$5.20-$7.60 -$2.40-$0.38--
11/13/2023Q3 2023-$5.60-$4.80+$0.80-$0.24--

Acurx Pharmaceuticals Earnings - Frequently Asked Questions

Acurx Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 11th, 2025 based off last year's report dates. Learn more on ACXP's earnings history.

In the previous quarter, Acurx Pharmaceuticals (NASDAQ:ACXP) reported ($1.89) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.00) by $0.11. Learn more on analysts' earnings estimate vs. ACXP's actual earnings.

The conference call for Acurx Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Acurx Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Acurx Pharmaceuticals (NASDAQ:ACXP) has a recorded net income of -$14.10 million. ACXP has generated -$10.69 earnings per share over the last four quarters.

Acurx Pharmaceuticals' earnings are expected to decrease from ($0.89) per share to ($2.06) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:ACXP) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners